China Universal Asset Management Co., Ltd. Atara Biotherapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$1.41 - $2.31 $1,838 - $3,012	1,304 Added 101.56%	2,588 $3,000
Q3 2023 Oct 30, 2023	BUY	$1.41 - $2.31 $1,838 - $3,012	1,304 Added 101.56%	2,588 $4,000
Q2 2023 May 21, 2024	SELL	$1.5 - $3.04 $24 - $48	-16 Reduced 1.23%	1,284 $2,000
Q2 2023 Jul 27, 2023	SELL	$1.5 - $3.04 $24 - $48	-16 Reduced 1.23%	1,284 $2,000
Q1 2023 May 21, 2024	BUY	$2.8 - $5.46 $940 - $1,834	336 Added 34.85%	1,300 $3,000
Q1 2023 Apr 27, 2023	BUY	$2.8 - $5.46 $940 - $1,834	336 Added 34.85%	1,300 $4,000
Q4 2022 May 21, 2024	BUY	$2.85 - $5.18 $2,747 - $4,993	964 New	964 $3,000
Q4 2022 Jan 31, 2023	BUY	$2.85 - $5.18 $230 - $419	81 Added 9.17%	964 $3,000
Q3 2022 Oct 21, 2022	BUY	$2.85 - $8.73 $2,516 - $7,708	883 New	883 $3,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.13B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account